IDH1 and glioma: In gliomas, IDH mutation correlates with decreased PD1/PD-L1 expression (Buege et al., 2018; Mu et al., 2018), and specific inhibitors of mutated IDH may improve the efficacy of immunotherapy in patients with IDH mutated gliomas (Kohanbash et al., 2017).